US4459286A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Coupled H. influenzae type B vaccine
Assignee: Merck and Co Inc
•
Filing: 1983-01-31
•
Granted: 1984-07-10
•
Expires: 2003-01-31
Abstract
Abstract Haemophilus influenzae type B polysaccharide is coupled through a spacer to a serotype outer membrane protein from Neisseria meningitidis. This conjugate has enhanced antigenicity and immunogenicity relative to the unconjugated polysaccharide.
Inventors
- 👤 Maurice R. Hilleman
- 👤 Joseph Y. Tai
- 👤 Richard L. Tolman
- 👤 Philip P. Vella
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 01:28
CPC Classifications
C; C12; C12P; C12P21/00; A; A61; A61K; A61K39/00; A61K39/02; A61K39/095; A61K39/102; A61K2039/60; A61K2039/6031; A61K2039/6068; A61K2039/62; A61K2039/627; Y; Y10; Y10S; Y10S530/00; Y10S530/806; Y10S530/807; Y10S530/82; Y10S530/825
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
29 words
A polysaccharide/protein conjugate which comprises H. influenzae type B polysaccharide and a T-cell stimulating N. meningitidis serotype outer membrane protein, said polysaccharide and protein being coupled through 6-aminocaproic acid.
Claim 2
Dependent Claim
29 words
A polysaccharide/protein conjugate which comprises H. influenzae type B polysaccharide and a T-cell stimulating N. meningitidis serotype outer membrane protein, said polysaccharide and protein being coupled through 6-aminocaproic acid.
Claim 3
Dependent Claim
17 words
A conjugate of claim 1 wherein the protein is N. meningitidis type B, serotype outer membrane protein.
Claim 4
Dependent Claim
62 words
A composition comprising an effective amount for either active or passive immunization of mammalian species, of the polysaccharide/protein conjugate which comprises H. influenzae type b polysaccharide and a T-cell-stimulating N. meningitidis serotype outer membrane protein, said polysaccharide and protein being coupled through 6-aminocaproic acid, antisera derived from said conjugate, or gammaglobulin or other antibody-containing fractions of said antisera, and a pharmaceutically-acceptable carrier.
Claim 5
Dependent Claim
62 words
A composition comprising an effective amount for either active or passive immunization of mammalian species, of the polysaccharide/protein conjugate which comprises H. influenzae type b polysaccharide and a T-cell-stimulating N. meningitidis serotype outer membrane protein, said polysaccharide and protein being coupled through 6-aminocaproic acid, antisera derived from said conjugate, or gammaglobulin or other antibody-containing fractions of said antisera, and a pharmaceutically-acceptable carrier.
Claim 6
Dependent Claim
10 words
A composition according to claim 3, further comprising an adjuvant.
Claim 7
Dependent Claim
16 words
A composition according to claim 3, wherein an effective amount is 2-50 μg of the conjugate.
Claim 8
Independent Claim
67 words
A method of treating mammalian species which comprises administering to said species an immunologically effective amount of a composition comprising a polysaccharide/protein conjugate which comprises H. influenza type b polysaccharide and a T-cell-stimulating N. meningitidis serotype outer membrane protein, said polysaccharide and protein being coupled through 6-aminocaproic acid, and a member of the group consisting of a pharmaceutically-acceptable carrier, an adjuvant, and a pharmaceutically-acceptable carrier and adjuvant.
Claim 9
Independent Claim
67 words
A method of treating mammalian species which comprises administering to said species an immunologically effective amount of a composition comprising a polysaccharide/protein conjugate which comprises H. influenza type b polysaccharide and a T-cell-stimulating N. meningitidis serotype outer membrane protein, said polysaccharide and protein being coupled through 6-aminocaproic acid, and a member of the group consisting of a pharmaceutically-acceptable carrier, an adjuvant, and a pharmaceutically-acceptable carrier and adjuvant.
Claim 10
Dependent Claim
34 words
The method according to claim 6 wherein the species to be treated is human neonates, and the effective amount of the composition per dose is an amount corresponding to 10 μg of the conjugate.
References Cited (Backward Citations)
US4220717A
Cited
US4271147A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-10 | 1988-01-09 | 1988-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-10 | 1992-01-09 | 1992-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-10 | 1996-01-09 | 1996-07-10 | $7700.00 | Window Closed / Lapsed |